UBS reiterates Buy on Option Care Health stock on execution focus

UBS reiterated its Buy rating and $39 price target on Option Care Health, implying roughly 60% upside from the $24.44 share price, citing above-market acute-care growth and improving chronic inflammatory disease trends. Option Care's Q2 adjusted EPS of $0.45 beat the $0.43 consensus and revenue of $1.44B exceeded the $1.42B estimate, although management narrowed full-year profit guidance and the EBITDA-guidance midpoint was lowered by 150bps. UBS sees delayed therapy starts in Q4 supporting an adjusted EBITDA ramp, with a more meaningful contribution expected in 2027, while lower acquisition valuations could support tuck-in M&A.

Analysis

OPCH’s setup is less about a single-quarter beat than whether it can convert higher patient census into durable EBITDA per case. Commercial-team investment and delayed therapy starts can lift utilization with modest incremental fixed cost, but specialty-drug mix, nursing capacity and payer reimbursement determine whether revenue growth translates into margin recovery. The key 1-3 month catalyst is fourth-quarter EBITDA conversion; a clean ramp would likely force bearish estimates higher, while another timing-related deferral would reinforce the market’s concern that the chronic portfolio has structurally lower earnings quality.

The more differentiated upside is consolidation: smaller independent infusion providers face increasing drug-inventory, reimbursement and labor burdens, making tuck-ins potentially accretive if acquired below OPCH’s own implied value. That would pressure private infusion operators and could marginally challenge CVS’s Coram and UNH/Optum’s site-of-care ambitions in selected therapies, though scaled payers retain negotiating leverage. Consensus appears to be treating management’s therapy timing as a near-term bridge; the contrarian risk is that payer prior-authorization tightening or manufacturer distribution changes convert it into a recurring delay cycle, limiting multiple expansion even if reported earnings meet guidance.

The sell-side target dispersion is not independently actionable without updated consensus EBITDA, organic-growth and reimbursement assumptions. Focus on whether fourth-quarter guidance implies sequential margin expansion rather than merely revenue recovery; that distinction determines whether OPCH deserves a rerating or remains a low-growth healthcare-services value trap over the next 6-18 months.

Key Decisions for Investors

• Watch, rather than initiate, OPCH ahead of the next earnings update: go long only if management quantifies therapy starts and guides to sequential fourth-quarter adjusted-EBITDA expansion with no further reduction in the full-year midpoint. Initial risk framework: 12-18% upside on estimate revisions versus 8-10% downside if the EBITDA ramp slips again.
• For a 1-3 month event trade, consider long OPCH versus short IHF only after confirmation of improving EBITDA conversion; this isolates company-specific execution from broader managed-care reimbursement volatility. Exit if chronic inflammatory census stops growing or payer-mix commentary deteriorates.
• Set an M&A alert for disclosed tuck-ins, purchase multiples and financing terms. Accretive deals funded from operating cash flow would support a 6-18 month rerating; equity-funded acquisitions or deals lacking disclosed synergy targets would falsify the capital-allocation upside case.
• Monitor CVS and UNH/Optum commentary on home-infusion reimbursement, prior authorization and provider-network strategy. Any broad payer restriction would be a sector-level negative for OPCH and should override a tactical long thesis.